Enter Symbol
Enter Search String
Analyst Comments: AGIX, Scientific Games, Sohu.com, Barclays, COSI, Cleveland-Cliffs,Potash Corp, Freddie Mac, OSI Pharma
By: Zacks Investment Research   Wednesday, October 08, 2008 8:44 AM
Sectors: Basic Materials , Computer and Technology , Finance , Industrial Products , Medical , Utilities
Symbols: AGIX, ANR, BCS, CLF, COSI, FRE, OSI, OSIP, PEG, SGMS, SOHU
Join Blog Network
Alerts by Email
Research Articles
Stock Ranking Changes
Related RSS Feeds

AGIX Headline Feed

AGIX Feed Add to Google: AGIX Feed Add to Yahoo: AGIX Feed

ANR Headline Feed

ANR Feed Add to Google: ANR Feed Add to Yahoo: ANR Feed

BCS Headline Feed

BCS Feed Add to Google: BCS Feed Add to Yahoo: BCS Feed

CLF Headline Feed

CLF Feed Add to Google: CLF Feed Add to Yahoo: CLF Feed

COSI Headline Feed

COSI Feed Add to Google: COSI Feed Add to Yahoo: COSI Feed

EML Headline Feed

EML Feed Add to Google: EML Feed Add to Yahoo: EML Feed

All Symbols

AGIX,ANR,BCS,CLF,COSI,EML,FRE,OSI,OSIP,PEG,SGMS,SOHU, Feed Add to Google: AGIX,ANR,BCS,CLF,COSI,EML,FRE,OSI,OSIP,PEG,SGMS,SOHU, Feed Add to Yahoo: AGIX,ANR,BCS,CLF,COSI,EML,FRE,OSI,OSIP,PEG,SGMS,SOHU, Feed

Sector Feeds:

submit article

AGIX Files for Chapter 11

For those of you still holding onto AtheroGenics (AGIX), the research-based pharmaceutical company with two clinical-stage drug development programs (according to Zacks senior drug industry analyst Jason Napodano, CFA, who published a report on AGIX last week), the company has just announced today it has filed for Chapter 11 bankruptcy.

The question now seems to be who, if anyone, will pick up the pieces of the late-phase candidates AGIX had been developing.? But for anyone shocked by today's announcement, they shouldn't be. From the same AGIX report: "The company recently released phase III data on lead compound AGI-1067 that did not meet the primary end point."

And this: "In September 2008 AtheroGenics announced it will not repay the its 4.5% Convertible Notes due September 2, 2008, nor will it make its scheduled interest payment on the 2008 Notes or the 4.5% Convertible Notes due March 1, 2011."

Scientific Games a Smart Play

Scientific Games (SGMS) has a leading position in several markets, including the instant ticket and online lottery markets. In addition, Scientific Games continues to win significant contracts in both the instant ticket and online lottery markets from both domestic and international lottery authorities.

Also, the company has made several acquisitions that have accelerated top-line growth. Ron Perelman, a world-renowned private investor, owns 28.1% of the company's stock. The Buy rating is maintained.

Scientific Games is currently selling at 20.6 times trailing 12 month earnings. Over the last few years, the stock has traded in a wide P/E range of 16 to 38. The stock traded with a significant P/E premium as a result of the company's leading market position. The six-month target price of $33.50 is based on a 30 P/E multiple on 12-month trailing earnings.

Sohu.com a Buy to $65

Sohu.com, Inc. (SOHU), is a leading online brand in China. Services provided by the company include news, search, e-mail, games and wireless messaging. The company offers services through one of the most comprehensive matrices of Chinese language web properties and proprietary search engines.

Although Sohu faces fierce competition from different fields including brand advertising, online games, wireless value-added services, and search, the company manages to be a main player in almost each field. Sohu has a well-known brand and rich website resources to leverage the great opportunities for online business in China.

Internet penetration is accelerating (in China), which is very positive for Sohu. Overall, we think the current stock price is undervalued. Therefore, we are maintaining a Buy rating on SOHU shares. Due to the current market malaise we are reducing our target price to $65.

Barclays Plc Kept a Hold

We are maintaining our Hold on Barclays PLC (BCS). The company will report its third quarter trading update on November 17.

We are reducing our EPADS estimates to $3.80 from $4.00 for 2008 and to $4.20 from $4.50 for 2009, mainly due to recent appreciation of the $ against other currencies.

Next Page >>

 

 
Rate :  Rate this Commentary  


 Number of Comments (0) Post Comment
 
  
Good Rating(+1)    Bad Rating(-1)
No Data Found

 
 
  Home | Login |Research | Earnings | Scans | Chat Rooms | Charts | Submit Article | Join Blog Network | Contributors | Subscribe to RSS

copryright 2008 all rights reserved